

Please amend claims 43-48 as follows.

43. (Twice Amended) A humanized catalytic antibody capable of degrading cocaine comprising a light chain wherein the amino acid sequence of complementarity determining region 1 is RSSXGTITXXNYAN (Seq ID NO: 73), the amino acid sequence of complementarity determining region 2 is XNNYRPP (Seq ID NO: 74) and the amino acid sequence of complementarity determining region 3 is ALWYSNHWV (Seq ID NO: 75) and a heavy chain wherein the amino acid sequence of complementarity determining region 1 is DYNMY (Seq ID NO: 76), the amino acid sequence of complementarity determining region 2 is YIDPXNGXXFYNQKFXG (Seq ID NO: 77) and the amino acid sequence of complementarity determining region 3 is GGGLFAX (Seq ID NO: 78).
44. (Twice Amended) A humanized polypeptide comprising a light chain domain which comprises a complementarity determining region 1 having the amino acid sequence RSSXGTITXXNYAN (Seq ID NO: 73), a complementarity determining region 2 having the amino acid sequence XNNYRPP (Seq ID NO: 74) and a complementarity determining region 3 having the amino acid sequence ALWYSNHWV (Seq ID NO: 75), interposed between appropriate framework regions, and linked to said light chain domain a heavy chain domain which comprises a complementarity determining region 1 having the amino acid sequence DYNMY (Seq ID NO: 76), a complementarity determining region 2 having the amino acid sequence YIDPXNGXIFYNQKFXG (Seq ID NO: 77) and a complementarity determining region 3 having the amino acid sequence GGGLFAX (Seq ID NO: 78) interposed between appropriate framework regions, said polypeptide having a conformation suitable for degrading cocaine.

45. (Twice Amended) A pharmaceutical composition for decreasing the concentration of cocaine in a subject which comprises an amount of the antibody of claim 41 effective to degrade cocaine in the subject and a pharmaceutically acceptable carrier.
46. (Twice Amended) A method of decreasing the concentration of cocaine in a subject which comprises administering to the subject an amount of the antibody of claim 41 effective to degrade cocaine in the subject, so as to thereby decrease the concentration of cocaine in the subject.
47. (Twice Amended) A pharmaceutical composition for treating cocaine overdose in a subject which comprises an amount of the antibody of claim 41 effective to degrade cocaine in the subject and a pharmaceutically acceptable carrier.
48. (Twice Amended) A method for treating cocaine overdose in a subject which comprises administering to the subject an amount of the antibody of claim 41 effective to degrade cocaine, so as to thereby treat cocaine overdose in the subject.

---

REMARKS

Claims 1, 21, and 41-48 are pending. Claims 1 and 21 have been canceled without prejudice. Claims 43-48 have been amended to introduce certain format changes. Support for these amendments may be found in the specification, *inter alia*, in Table 3 at page 49. Applicants submit that these amendments raise no issue of new matter. Thus, claims 41-48 are now pending and under examination.